Avecho Biotechnology Limited Overview
Avecho is a Melbourne-based, clinical-stage specialty pharmaceutical micro-cap. It builds products on a proprietary, patented vitamin-E-derived excipient, Tocopheryl Phosphate Mixture (TPM®), which improves the solubility and the oral, dermal and transdermal absorption of drugs and nutrients. Its value now rests almost entirely on one asset: a TPM-enhanced cannabidiol (CBD) soft-gel capsule in a pivotal Phase III trial for insomnia. The trial is designed to support registration with Australia's TGA under the low-dose, over-the-counter (Schedule 3) CBD pathway. A 10-year exclusive Australian licence with Sandoz (US$3M upfront, up to US$16M in milestones, 14–19% royalties) validates the asset commercially. A positive interim analysis in June 2026, which continued the trial without increasing the sample size, materially de-risked it. Underneath sits a small legacy ingredients business, selling TPM® and Vital ET® to a concentrated customer base, which generates roughly A$0.5–1.2M a year. Avecho is therefore a binary, event-driven biotech, funded by equity, R&D tax refunds and licence income.
Company's own description [AR25, Principal activities].
Avecho describes itself as developing and commercialising innovative human and animal health products using TPM®. TPM is derived from vitamin E through proprietary, patented processes and enhances the solubility and the oral, dermal and transdermal absorption of drugs and nutrients. The company names its lead asset as a proprietary CBD TPM soft-gel capsule, shown to increase CBD absorption and now in Phase III development for insomnia.
Independent characterisation.
In practice, Avecho runs three economic engines of very different size and maturity.
-
Clinical development (Human Health segment). This is where most capital goes and where most enterprise value sits. Spending is concentrated on the Phase III CBD-TPM insomnia program. Clinical development expenses were A$3.48M of the A$4.31M FY2025 R&D budget [AR25 Note 7]. The model is develop-and-license: Avecho runs the trial and the regulatory work, out-licenses commercial rights by territory, and keeps manufacturing and supply through third-party CMOs. Under the Sandoz agreement, Avecho will sell finished product to Sandoz and also receive royalties [AR25].
-
Ingredient production (Production segment). Avecho has TPM® and Vital ET® made and sells them wholesale at a fixed price per kilogram. Vital ET® is a cosmetic/skin-care ingredient; TPM® serves as a drug-delivery excipient. Revenue is lumpy and highly concentrated: about 97% of FY2025 Production revenue came from a single external customer group (FY2024: 96%; FY2023: 85%; FY2022: 92%) [AR25; AR23]. The going-concern notes name Ashland and Themis as customers [AR25; AR23].
-
Licensing and royalties (legacy). These are historical out-licences of TPM formulations. They include a 5% royalty on net sales of TPM-daptomycin from Mylan (now Viatris), set by the December 2018 settlement, and partner-funded programs such as Perrigo's TPM-ibuprofen gel and Arthur Group's oncology solubilisation work. Licence revenue has been immaterial: A$69,262 in FY2022 and nil since [AR23; AR25].
Revenue model mix (FY2025) [AR25 Note 5].
The Sandoz upfront payment (A$4,832,762) is held as a non-current contract liability. It is not yet revenue and will be recognised as performance obligations under the development and licensing agreement are satisfied [AR25 Note 15; HY26].
Non-operating funding stream. Australia's refundable R&D Tax Incentive (an 18.5% premium above the company tax rate for entities with turnover under A$20M) is structurally important:
-
FY2025 R&D tax incentive income: A$1,995,884, which exceeds product revenue [AR25].
-
The refund is typically pre-funded through R&D advance facilities from Endpoints Capital (15.8% interest on the FY2024 facility) [AR25 Note 13].
Value-chain position.
Avecho is an IP owner and integrator. It owns the excipient process patents and formulation know-how, outsources GMP manufacture (Procaps Group for the CBD soft-gels [AR23]; an Australian third-party GMP CMO for the ibuprofen gel [AR23]), and outsources clinical operations to Australian trial sites. It relies on partners such as Sandoz for distribution and commercialisation.
Customer types and end-markets.
Strategy
Stated strategic themes [AR25; ASX releases 2025–26]. The company's strategy rests on five themes, paraphrased from its own disclosures:
-
Complete Phase III and file with the TGA. The trial is the company's final clinical step before a TGA submission to register the CBD-TPM capsule for insomnia.
-
Be first to market in Australia's OTC CBD category. The company wants to be first through the TGA's unique Schedule 3 over-the-counter CBD pathway and estimates the market could exceed US$125M a year [ASX 2 Mar 2026; 21 May 2026].
-
License territory by territory. Following the Sandoz deal, business development has broadened to other international markets, with "licensing discussions remain active across multiple jurisdictions" [AR25]. The interim result is said to strengthen the licensing position outside Australia [ASX 24 Jun 2026].
-
Prepare manufacturing before the data. The A$2.5M placement funded registration batches for long-term stability, scale-up to commercial batch size, regulatory manufacturing documentation and capsules for the second Phase III cohort. The aim is to lodge with the TGA as soon as possible after a positive outcome [AR25].
-
Engage global regulators. The company plans engagement with the US FDA and European authorities to define regional development paths [3P: Biotech Dispatch; Sleep Review].
Strategic initiatives in the last 24 months.
ESG and sustainability commitments. No formal ESG framework, emissions targets or sustainability report have been published. Disclosures are limited to environmental compliance on chemical waste [AR25].
Cost programs. None announced; the cost base is already minimal (about 15 staff).
Medium-term financial targets and guidance. No financial guidance or medium-term revenue or margin targets are provided. Operational guidance:
-
FY2025 report: interim analysis targeted for H1 2026. Delivered 24 Jun 2026.
-
AGM and interim deck: complete Phase III dosing to the final patient (H2 2026 trial continuation), then final analysis and TGA submission. Specific dates for top-line results and submission are not publicly disclosed.
Products & Services
Platform technology
| Product | Description and capabilities | Target customer | Status / year | Pricing |
|---|---|---|---|---|
| TPM® (Tocopheryl Phosphate Mixture) | Vitamin-E-derived mixture of tocopheryl phosphates made by a proprietary, patented process. Improves solubility and oral, dermal and transdermal absorption. Historically also branded "Targeted Penetration Matrix". | Pharma and consumer-health formulators; Avecho's own pipeline | Commercial excipient. US manufacturing-process patent allowed May 2023, running to at least Dec 2037 | Fixed price per kg; 50% deposit and 50% on delivery [AR25 Note 5] |
Production segment (commercial)
| Product | Description | Customer | Status | Pricing / terms |
|---|---|---|---|---|
| Vital ET® | TPM-based vitamin E ingredient for skin-care and cosmetic formulations | Ashland (global speciality ingredients); single customer group about 97% of segment revenue | Commercial; main source of FY2025 revenue ("revenue consisted mainly of Vital ET® sales") | Fixed price per kg; 45-day terms [AR25] |
| TPM® bulk excipient | Excipient supplied to licensees | Themis Medicare (India); Viatris/Mylan (exclusive TPM sourcing for TPM-daptomycin, per 2018 settlement) | Commercial, small volumes. India revenue A$22,500 in FY2025 | Fixed price per kg |
Human Health — lead clinical asset
| Product | Description and specifications | Target | Stage / latest | Commercial terms |
|---|---|---|---|---|
| CBD TPM® soft-gel capsule (insomnia) | Oral cannabidiol in a TPM-enhanced soft-gel, shown to increase CBD absorption. Doses 75 mg and 150 mg nightly. Made by Procaps Group (US CMO); registration and commercial batches under way (FY2025 placement) | Adults with insomnia. Initially Australian pharmacy OTC (Schedule 3) channel, then international | Pivotal Phase III, multi-centre, randomised, double-blind, placebo-controlled; target 519 participants; 8-week treatment. Positive interim analysis 24 Jun 2026; second cohort recruiting from 31 Aug 2026 | Australia licensed to Sandoz (10 yrs): US$3M upfront, up to US$16M development milestones, 14–19% tiered royalties, Avecho supplies product. Rest of world retained (Sandoz ROFR) [AR25] |
Human Health — cannabinoid portfolio (secondary)
| Product | Description | Status |
|---|---|---|
| CBD TPM oral oil | TPM-enhanced oral cannabinoid oil | Developed; part of four-dosage-form portfolio [AR23] |
| TPM cannabinoid gummies (edibles) | First-generation glycerin/gelatin chewables with TPM-enhanced cannabinoids | Development completed Jun 2023; aimed at North American medicinal and recreational markets [AR23] |
| TPM topical cannabinoid gel | Dermal cannabinoid delivery | Developed [AR23] |
| CBD supplied to academic research (Lambert Initiative, University of Sydney) | Avecho's oral CBD product used for novel indications not previously linked to CBD | Avecho estimated its products would be used in seven clinical trials during 2023 [3P: SmallCaps 2023] |
Human Health — partnered / legacy TPM formulations
| Product | Partner | Description | Status |
|---|---|---|---|
| TPM®-ibuprofen topical gel | Perrigo Company plc (NYSE: PRGO) | Topical NSAID gel for a US pain indication; Avecho manages Australian GMP manufacture | Partner-funded development (2023 onward); current status not updated in FY2025 report |
| TPM-daptomycin injectable | Viatris (formerly Mylan) | TPM-solubilised antibiotic | Mylan holds full rights; 5% royalty on net sales and exclusive TPM supply (Dec 2018 settlement). No royalty revenue reported FY2022–FY2025 |
| TPM®-phytonadione injection (vitamin K1) | Athenex → (Sagent) | Injectable; FDA pre-IND feedback said existing TPM toxicology appeared sufficient | Partnership dissolved after Sagent bought Athenex injectables (Jun 2023) [AR23] |
| TPM-solubilised oncology drugs | Arthur Group (US) | Optimised cancer drug solubilisation, work done at Arthur Group's US facility | Licence and development agreement May 2023 [AR23] |
| TPM/Oxycodone transdermal patch | — | Opioid patch for postherpetic neuralgia pain | Legacy (Phosphagenics era); early clinical work completed; not active in recent reports |
| TPM/Oxymorphone patch | — | Opioid transdermal | Legacy; early clinical |
| Transdermal patch collaboration | Terumo | Patch delivery using TPM | Legacy (2017); current status not publicly disclosed |
Animal Health & Nutrition
| Product | Description | Status |
|---|---|---|
| TPM feed additive | Improves feed efficiency and livestock health (poultry and pig field trials historically) | Minimal activity; not separately monitored [AR25 Note 4; AR23] |
Financial Narrative
The FY2022–FY2025 line items come from the audited statements in [AR23] and [AR25]. FY2021 is limited to what is disclosed in the five-year tables and the opening balances in those reports. Avecho does not report EBITDA, operating income or ROIC as defined lines. These are derived as follows:
-
Operating income (EBIT) = loss before tax + finance costs.
-
EBITDA = EBIT + depreciation and amortisation (D&A from Note 4).
-
Interest income sits within "R&D tax incentive and other income" and is not stripped out.
Income statement (A$)
FY2021 line items other than revenue, net loss and EPS were not available in the sources reviewed.
Margins and growth (%)
Revenue CAGR FY2021–FY2025: about 11.8% a year (A$0.79M to A$1.24M).
Long view: FY2019 revenue was A$4.24M [AR23], so the 6-year trajectory is down.
Commentary — income statement. Revenue has swung with one dominant customer's ordering cycle:
-
FY2023 fell 58% "primarily due to a reduction in Vital ET® sales" [AR23].
-
FY2024 more than doubled.
-
H1 FY2026 collapsed to A$59.6k [HY26], so FY2026 revenue is likely to fall sharply unless second-half orders recover.
Gross margin is structurally high (60–72%) in normal years. FY2023 was negative because of inventory impairment.
The cost base has stepped up with the Phase III program:
-
R&D rose from A$1.59M (FY2022) to A$4.31M (FY2025), a 2.7x increase.
-
Clinical development expense alone rose from A$0.92M to A$3.48M [AR23 Note 7; AR25 Note 7].
-
The R&D tax incentive offsets about 46% of R&D spend (A$2.00M / A$4.31M in FY2025).
FY2025 finance costs jumped to A$461k, from A$57k. The FY2024 Endpoints facility accounts for only A$111,706 of interest [AR25 Note 13]; the rest likely reflects foreign-exchange losses on the USD-denominated Sandoz cash. Under the accounting policy, FX losses on borrowings sit in finance costs, and the A$3.9M USD exposure is disclosed in Note 18. This is our inference: the split is not explicitly disclosed.
Admin costs rose 27% in FY2025, driven by share-based payments (A$393,705 versus A$14,017), payroll and investor relations [AR25].
Balance sheet (A$, at 31 December)
FY2021 figures are the 1 Jan 2022 opening balances from [AR23]: cash from the cash-flow statement, and equity, issued capital and accumulated losses from the statement of changes in equity. Other FY2021 balance-sheet lines were not available in the sources reviewed.
Commentary — balance sheet. The balance sheet is very simple: cash plus the R&D refund receivable, against small payables and employee provisions, plus the Sandoz deferred revenue.
-
Accumulated losses of A$273.8M against issued capital of A$246.9M show how much capital the Phosphagenics/Avecho platform has absorbed over three decades.
-
FY2025 equity of A$1.56M understates economic net worth. The A$4.83M Sandoz contract liability is non-cash and will unwind into revenue rather than require cash repayment.
-
Unrecognised deferred tax assets total A$48.0M, including A$47.4M of tax losses at 25% [AR25 Note 9]. This latent asset is usable only if the company becomes profitable and passes continuity tests.
-
There are no goodwill or capitalised intangibles; all R&D is expensed.
Cash flow (A$)
FY2021 cash-flow detail was not available in the sources reviewed.
Commentary — cash flow. FY2025 is the only year of positive operating cash flow, and it is distorted. Customer receipts of A$6.49M include the ~A$4.79M Sandoz upfront. Excluding Sandoz, underlying operating cash burn was roughly A$3.7M, consistent with FY2024 (A$3.97M).
The steady-state burn is therefore about A$3.5–4.5M a year, partly offset by annual R&D refunds of A$1.7–2.0M received around May. That implies net funding needs of roughly A$2–2.5M a year before trial-completion and registration costs.
2026 liquidity events:
-
Cash was A$4.4M at 31 Mar 2026 [ASX 12 May 2026].
-
The company then received ~A$1.9M from option exercises and A$1.98M from the FY2025 R&D refund, of which A$1.62M repaid Endpoint Capital [ASX 22 May 2026].
-
Cash stood at A$6.6M at 30 Jun 2026 [Q2-26].
Ratios
Notes on the ratios:
-
ROA for FY2022 needs FY2021 total assets, which were not available.
-
ROIC is not meaningful: invested capital is negative or near zero excluding cash, and NOPAT is negative.
-
Net debt/EBITDA is not meaningful: the company has net cash and negative EBITDA.
-
Interest coverage is negative and shown only for completeness.
-
A cash conversion cycle is not meaningful given immaterial inventory and receivables; it is not disclosed.
-
The FY2025 ROE matches the Tiger aggregator figure of -182.91% [3P].
Ratio commentary. Standard profitability ratios carry little information for a pre-commercial biotech. The decision-relevant metrics are:
Runway: A$6.6M cash against a net burn of ~A$1–1.5M a quarter, implying about 4–6 quarters before Phase III completion costs rise.
Funding dependence: 100% reliance on equity, R&D refunds and licence payments.
Leverage: negligible. Debt is effectively limited to small leases and periodic R&D advances, which are self-liquidating against refunds.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (AUD) and Segment Margins & Growth (%)
| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Production revenue (AUD) | 1,129,260 | 473,551 | 1,132,672 | 1,237,762 |
Human Health revenue (AUD) | 0 | 0 | 0 | 0 |
Total revenue (AUD) | 1,129,260 | 473,551 | 1,132,672 | 1,237,762 |
Production % of total revenue | 100 | 100 | 100 | 100 |
Production revenue YoY growth (%) | 42.3 | -58.1 | 139.2 | 9.3 |
Revenue by Segment (AUD) and Segment Margins & Growth (%) — Production PBT
| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Production PBT (AUD) | 660,278 | -338,173 | 459,997 | 394,900 |
Human Health PBT (AUD) | -999,541 | -1,080,775 | -1,888,297 | -2,388,259 |
Corporate PBT (AUD) | -2,003,128 | -2,017,613 | -1,693,748 | -2,423,264 |
Group loss before tax (AUD) | -2,342,391 | -3,436,561 | -3,122,048 | -4,416,623 |
Production PBT margin (%) | 58.5 | -71.4 | 40.6 | 31.9 |
Segment Assets & Liabilities (AUD)
| Item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Production segment assets (AUD) | 1,231,542 | 138,630 | 1,067,058 | 1,912,017 |
Human Health segment assets (AUD) | 687,927 | 1,076,206 | 1,645,372 | 1,982,754 |
Corporate segment assets (AUD) | 1,426,083 | 6,104,474 | 2,284,361 | 3,211,282 |
Human Health segment liabilities (AUD) | 131,439 | 213,413 | 978,443 | 4,964,201 |
Income Statement (AUD) and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (AUD) | 793,600 | 1,129,260 | 473,551 | 1,132,672 | 1,237,762 |
Cost of sales (AUD) | — | 336,142 | 517,346 | 460,746 | 349,386 |
Gross profit (AUD) | — | 793,118 | -43,795 | 671,926 | 888,376 |
R&D tax incentive and other income (AUD) | — | 727,823 | 1,167,984 | 1,893,782 | 2,049,038 |
of which R&D tax incentive (AUD) | — | 622,923 | 1,075,567 | 1,635,464 | 1,995,884 |
R&D expenses (AUD) | — | 1,593,880 | 2,117,263 | 3,591,156 | 4,311,137 |
Administration and corporate expenses (AUD) | — | 2,263,103 | 2,428,131 | 2,039,467 | 2,581,540 |
Finance costs (AUD) | — | 6,349 | 15,356 | 57,133 | 461,360 |
Depreciation and amortisation (AUD) | — | 230,351 | 178,695 | 144,885 | 137,089 |
Operating income / EBIT, derived (AUD) | — | -2,336,042 | -3,421,205 | -3,064,915 | -3,955,263 |
EBITDA, derived (AUD) | — | -2,105,691 | -3,242,510 | -2,920,030 | -3,818,174 |
Pre-tax income (AUD) | -3,416,116 | -2,342,391 | -3,436,561 | -3,122,048 | -4,416,623 |
Income tax expense (AUD) | — | 0 | 0 | 0 | 0 |
Net income (AUD) | -3,416,116 | -2,342,391 | -3,436,561 | -3,122,048 | -4,416,623 |
EPS basic (A$ cents) | -0.19 | -0.13 | -0.15 | -0.10 | -0.14 |
EPS diluted (A$ cents) | -0.19 | -0.13 | -0.15 | -0.10 | -0.14 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | — | 42.3 | -58.1 | 139.2 | 9.3 |
Gross margin (%) | — | 70.2 | -9.2 | 59.3 | 71.8 |
Operating (EBIT) margin (%) | — | -206.9 | -722.5 | -270.6 | -319.6 |
EBITDA margin (%) | — | -186.5 | -684.7 | -257.8 | -308.5 |
Net margin (%) | -430.5 | -207.4 | -725.7 | -275.6 | -356.8 |
Balance Sheet (AUD) and Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD) | 3,264,764 | 1,468,210 | 5,504,396 | 2,374,534 | 4,663,491 |
Trade and other receivables (AUD) | — | 745,994 | 1,099,563 | 2,246,461 | 2,204,549 |
Inventories (AUD) | — | 401,979 | 97,117 | 137,459 | 8,066 |
Total current assets (AUD) | — | 2,851,189 | 7,003,642 | 4,810,277 | 7,056,628 |
Total assets (AUD) | — | 3,345,552 | 7,319,310 | 4,996,791 | 7,106,053 |
Short-term debt incl. current leases (AUD) | — | 70,923 | 76,926 | 1,062,196 | 14,473 |
Long-term debt incl. non-current leases (AUD) | — | 175,152 | 98,225 | 14,472 | 0 |
Total debt incl. leases (AUD) | — | 246,075 | 175,151 | 1,076,668 | 14,473 |
Net debt, negative = net cash (AUD) | — | -1,222,135 | -5,329,245 | -1,297,866 | -4,649,018 |
Contract liabilities (AUD) | — | 0 | 158,376 | 0 | 4,832,762 |
Total liabilities (AUD) | — | 920,656 | 941,540 | 1,727,053 | 5,546,403 |
Total equity (AUD) | 4,536,590 | 2,424,896 | 6,377,770 | 3,269,738 | 1,559,650 |
Goodwill and intangibles (AUD) | — | 26,250 | 0 | 0 | 0 |
Working capital (AUD) | — | 2,105,685 | 6,160,327 | 3,099,882 | 6,347,425 |
Issued capital (AUD) | 237,601,871 | 237,528,800 | 244,605,505 | 244,605,505 | 246,901,334 |
Accumulated losses (AUD) | 262,067,262 | 264,104,330 | 267,440,391 | 269,391,751 | 273,808,374 |
Shares on issue (millions) | 1,836.1 | 1,837.9 | 3,169.3 | 3,169.3 | 3,673.5 |
NTA per share (A$ cents) | — | 0.13 | 0.20 | 0.10 | 0.04 |
Cash Flow (AUD)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD) | — | -1,665,207 | -3,179,955 | -3,968,718 | 1,103,098 |
Receipts from customers incl. GST (AUD) | — | 1,192,827 | 758,215 | 566,234 | 6,491,167 |
R&D tax incentive and EMDG receipts (AUD) | — | 1,039,938 | 723,888 | 1,066,298 | 1,695,102 |
Capital expenditure (AUD) | — | 53,124 | 0 | 0 | 0 |
Free cash flow (AUD) | — | -1,718,331 | -3,179,955 | -3,968,718 | 1,103,098 |
Proceeds from share issues, gross (AUD) | — | 1,989 | 8,003,594 | 0 | 2,500,000 |
Borrowings received / (repaid) net (AUD) | — | 0 | 0 | 931,512 | -1,043,218 |
Net cash from financing (AUD) | — | -78,223 | 7,216,141 | 854,586 | 1,185,859 |
Dividends paid (AUD) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD) | — | -1,796,554 | 4,036,186 | -3,129,862 | 2,288,957 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, average equity (%) | -67.3 | -78.1 | -64.7 | -182.9 |
ROA, average assets (%) | — | -64.4 | -50.7 | -73.0 |
Current ratio (x) | 3.82 | 8.31 | 2.81 | 9.95 |
Debt / equity incl. leases (x) | 0.10 | 0.03 | 0.33 | 0.01 |
Interest coverage, EBIT / finance costs (x) | -367.9 | -222.8 | -53.6 | -8.6 |
Asset turnover, revenue / average assets (x) | — | 0.09 | 0.18 | 0.20 |
R&D tax incentive / R&D expense (%) | 39.1 | 50.8 | 45.5 | 46.3 |
Revenue by Region (AUD)
| Region / country | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Australia (AUD) | 24,550 | 38,307 | 38,167 | 136,983 |
Switzerland (AUD) | 1,009,945 | 403,444 | 352,622 | 1,068,532 |
Americas incl. United States (AUD) | 69,263 | 0 | 708,540 | 0 |
India (AUD) | 25,502 | 31,800 | 33,343 | 22,500 |
France (AUD) | 0 | 0 | 0 | 9,747 |
Total (AUD) | 1,129,260 | 473,551 | 1,132,672 | 1,237,762 |
Revenue by Region (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
APAC, Australia plus India (%) | 4.4 | 14.8 | 6.3 | 12.9 |
EMEA, Switzerland plus France (%) | 89.4 | 85.2 | 31.1 | 87.1 |
Americas (%) | 6.1 | 0.0 | 62.6 | 0.0 |
Revenue by Region (%) (FY2023–FY2025)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Australia (%) | 56.0 | -0.4 | 258.9 |
Switzerland (%) | -60.1 | -12.6 | 203.0 |
India (%) | 24.7 | 4.9 | -32.5 |
Per-Share Data and Share Count (millions)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Share price at year end (A$ cents) | 1.50 | 1.50 | 0.35 | 0.25 | 0.90 |
Shares on issue at year end (millions) | 1,836.1 | 1,837.9 | 3,169.3 | 3,169.3 | 3,673.5 |
Market cap at year end, derived (AUD Mn) | 27.5 | 27.6 | 11.1 | 7.9 | 33.1 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Recent price | A$0.018–0.020 (late Sep / early Oct 2026) | [3P: Tiger; InvestSMART] |
52-week range | A$0.003 – A$0.027 | [3P: Tiger] |
Market cap | About A$69–77M | [3P] |
Enterprise value (market cap less A$6.6M cash) | About A$62–70M | Derived |
1-year performance | Roughly +280% to +390% (from ~A$0.004–0.005 in Oct 2025); Market Index cites +386% relative to the ASX 200 over 1 year | [3P: Market Index; ASX 23 Oct 2025 placement pricing] |
3-year performance | Roughly +200% to +400% (from ~A$0.004–0.006 in late 2023) | Derived from placement and year-end prices; approximate |
5-year performance | Roughly +20% to +30% (from ~1.5c at end-2021) | Derived; approximate |
Valuation Multiples
| Multiple | Avecho | Comment |
|---|---|---|
P/E | Not meaningful (loss-making; Tiger shows -12.9x LYR) | [3P] |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
EV/Sales (TTM revenue ~A$0.74M) | About 85–95x | TTM = FY2025 − H1 FY2025 + H1 FY2026 |
P/B | About 44x | [3P: Tiger 44.21] |
Analyst Conclusions
Management guidance. There is no financial guidance. Operational guidance is to:
-
complete recruitment and dosing of the second cohort (recruitment restarted 31 Aug 2026, with additional sites);
-
reach the final analysis;
-
lodge a TGA submission as soon as possible after a positive result, supported by registration batches already under way;
-
progress ex-Australia licensing and FDA/EU regulatory engagement.
Consensus. None available.
Bull case
-
The interim pass is genuinely informative. The DMB required no increase in sample size, which the company says shows the treatment effect and variability are tracking the trial's design assumptions. This raises the probability of final success above typical Phase III base rates.
-
The economics are asymmetric. Up to US$16M in Sandoz milestones, 14–19% royalties plus supply margin in Australia, and fully retained rest-of-world rights could each be worth more than the current EV of about A$65M if the final data are positive. The new BD capability and the post-interim momentum improve the odds of a second licence.
-
Funding risk is lower than history suggests. With A$6.6M cash, annual R&D refunds of about A$2M, no debt and the option overhang gone, the company can probably reach the final readout with modest or no further dilution, particularly if a licence deal brings upfront cash.
Bear case
-
CBD has a poor sleep-trial record and Avecho is still blinded. A "continue" recommendation does not confirm efficacy, and peers' Phase III CBD sleep studies failed. A final miss would leave only a sub-A$1.5M ingredient business.
-
Regulatory and commercial novelty. The TGA has never registered a CBD pharmaceutical. Schedule 3 pricing, pharmacist uptake and competition from melatonin and other sleep aids are unproven, and the US$125M market estimate is the company's own.
-
Thin margin for error. The share price has risen roughly 4x in a year (P/B about 44x; EV/Sales about 90x on collapsing ingredient revenue). Going-concern language, 97% customer concentration and a history of deep-discount raises point to downside if timelines slip again; the interim itself arrived about 18 months late.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| September 2026 quarterly 4C | By 31 Oct 2026 | Cash runway and recruitment rate for the second cohort |
| Recruitment completion and last-patient-last-dose | H2 2026 – 2027 (not specified) | Sets the timing of the final readout |
| Ex-Australia licensing deal(s) | Any time; BD hire Aug 2026 | Non-dilutive cash; tests whether Sandoz exercises its ROFR |
| FDA / EU regulatory feedback | Post-interim | Defines the size of global opportunity |
| FY2026 R&D tax refund | About May 2027 | About A$1.5–2.0M of funding |
| FY2026 annual report | Late Feb 2027 | Going-concern status; Sandoz revenue recognition |
| Final Phase III top-line | After completion (not dated) | Binary value event |
| TGA submission | After positive top-line | Triggers Sandoz development milestones |
| Board renewal | 2026–2027 | Restore a fourth director and committee structure |
| Ingredient orders (Vital ET®) | H2 2026 | Whether H1 FY2026 weakness was timing or structural |
Analyst verdict
Avecho has become a single-asset, event-driven biotech. Its investment case rests almost entirely on whether a TPM-enhanced CBD capsule can show statistically robust efficacy in insomnia in a 519-patient pivotal trial. The June 2026 interim analysis materially changed the risk profile. An independent DMB saw unblinded data from 244 patients and recommended continuing without enlarging the study, with no serious adverse events. In adaptive designs, a weak or noisy signal usually triggers a sample-size increase, so this outcome is meaningfully positive. It is still not proof of efficacy, and investors should resist treating it as such, especially given CBD's record of failed sleep trials.
Commercially, the Sandoz agreement gives unusual validation for a company of Avecho's size. Its royalty band of 14–19%, plus supply margin and US$16M in milestones, is attractive, and rest-of-world rights remain unencumbered apart from Sandoz's ROFR. The balance sheet is more stable than at any point since 2023: A$6.6M cash, no debt, the AVEOA overhang removed and dependable R&D refunds. Governance and operations are thin, though. The board has three directors and no committees, revenue depends on one customer, and the ingredient business that once anchored the company has shrunk to near-irrelevance in H1 FY2026.
At about A$65–70M EV, the market is already pricing a reasonable chance of success after a roughly fourfold re-rating. On our assessment, the risk-reward is now balanced to modestly positive for investors who can tolerate binary outcomes. The upside depends on confirmatory top-line data, an ex-Australia licence, and a clear TGA path to the first Schedule 3 CBD registration. The downside is a final-readout miss, which would likely erase most of the value. We would track the quarterly recruitment cadence, cash burn and any licensing announcement as the leading indicators.
All figures are from public filings and reputable aggregators as cited. Nothing here constitutes investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Base salary (31 Dec 2025, incl. super) |
|---|---|---|---|---|
Dr Paul Gavin, BSc (Hons), PhD | Chief Executive Officer | CEO since 1 May 2020; previously Chief Scientific Officer | Long-standing Avecho/Phosphagenics scientist and TPM technology lead | A$380,000; 6-month notice [AR25] |
Dr Roksan Libinaki, PhD | Chief Operating Officer | KMP throughout FY2022–FY2025 | Long-serving Avecho scientific and operations executive | A$280,000; 3-month notice [AR25] |
Naomi Lawrie | Company Secretary | Appointed Jun quarter 2026, replacing Melanie Leydin (Vistra) | Company secretarial professional | — |
Eve Williamson | Strategic Business Development Consultant (not KMP) | Appointed 24 Aug 2026 | Senior pharmaceutical executive with portfolio strategy and commercial leadership experience | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Background | Independence | Other listed boards |
|---|---|---|---|---|---|
Dr Gregory Collier, PhD | Non-Executive Chairman | Chair since at least 2017 [3P: Biotech Daily] | 25+ years in pharma R&D and commercialisation. Former CEO of ChemGenex (sold to Cephalon for A$230M in 2011). Inaugural Alfred Deakin Professor; 150+ publications; 33 patents; Roche Award of Excellence 2010 | Independent NED | — |
Dr Ross Murdoch, BSc (Hons), PhD, GAICD | Non-Executive Director | Director since Apr 2015 | Former Avecho CEO (Jan 2015 – Mar 2019); ex-SVP Shire (USA/Switzerland); ex-President and COO of Prana Biotechnology | Non-executive. Not independent under the ASX three-year look-back until 2022; now arguably independent | — |
Ms Kathy Connell, GAICD | Non-Executive Director | c.Apr 2024 | Former BD, licensing and external-innovation lead at J&J and Sanofi in ANZ (over US$1B deployed); Korn Ferry; registered psychologist; co-founder of Medicines Australia's PAIG; BioMelbourne Woman of the Year 2018 | Independent NED | Opthea Ltd (ASX/NASDAQ: OPT); also Proto Axiom, BioNSW |
Mr Matthew McNamara, BSc (Hons), MBA, GAICD | Former Non-Executive Director | 13 Jan 2020 – resigned Jun quarter 2026 | CIO of Horizon 3 Healthcare, which invested in Avecho through trustee Melbourne Securities Corporation [AR23] | Was nominee-linked | — |
Directors' Remuneration
| Name | Salary / fees | Leave accruals | Bonus (shares) | Superannuation | Long service leave | Options (share-based) | Total FY2025 | Total FY2024 |
|---|---|---|---|---|---|---|---|---|
Gregory Collier | 100,000 | 0 | 0 | 0 | 0 | 16,194 | 116,194 | 100,000 |
Ross Murdoch | 50,032 | 0 | 0 | 5,878 | 0 | 8,097 | 64,007 | 55,263 |
Matthew McNamara | 50,032 | 0 | 0 | 5,878 | 0 | 8,097 | 64,007 | 55,263 |
Kathy Connell | 50,032 | 0 | 0 | 5,878 | 0 | 12,438 | 68,348 | 46,053 |
Paul Gavin (CEO) | 362,500 | 17,108 | 12,500 | 41,125 | 55,378 | 161,940 | 650,551 | 256,823 |
Roksan Libinaki (COO) | 262,500 | -13,197 | 12,500 | 29,375 | -611 | 80,970 | 371,537 | 302,323 |
Total | 875,096 | 3,911 | 25,000 | 88,134 | 54,767 | 287,736 | 1,334,644 | 815,725 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
c.Apr 2024 | Kathy Connell joins board | Adds global licensing and BD expertise before the out-licensing push |
Jun quarter 2026 | Matthew McNamara resigns | Removes the Horizon 3 Healthcare-linked director; board falls to three [Q2-26] |
Jun quarter 2026 | Naomi Lawrie replaces Melanie Leydin as Company Secretary | Administrative [Q2-26] |
24 Aug 2026 | Eve Williamson engaged as senior BD consultant | Builds out-licensing capability after the positive interim result [ASX 24 Aug 2026] |
Major Shareholders
| Holder | Shares | Stake | Date | Source |
|---|---|---|---|---|
Mark Gregory Kerr and associates (incl. Linda Kerr) | 349,133,188 | 9.50% | Notice dated 18 Feb 2026 (dilution-driven; previously 11.00% at 19 Jun 2025 and 11.02% at 12 Feb 2024) | [3P: Market Index; InvestSMART; TipRanks] |
Major Shareholders by Rank
| Rank | Holder | Shares | Approx. stake |
|---|---|---|---|
| 1 | Chunyan Niu | 252,000,000 | 6.9% |
| 2 | Mark Kerr | 174,566,594 | 4.8% |
| 3 | Linda Kerr | 174,566,594 | 4.8% |
| 4 | Melbourne Securities Corporation Ltd (trustee for Horizon 3 Healthcare) | 101,012,290 | 2.8% |
| 5 | Rosscope Pty Ltd | 85,513,129 | 2.3% |
| 6 | Wayne Kent | 50,000,000 | 1.4% |
| 7 | Servbond Pty Ltd | 47,000,000 | 1.3% |
| 8 | Brandon Batagol | 44,532,406 | 1.2% |
| 9 | 10 Bolivianos Pty Ltd | 43,796,359 | 1.2% |
| 10 | Sked Proprietary Ltd | 42,000,000 | 1.1% |
Shareholding Trend
| Holder | Shares at 31 Dec 2025 | Options at 31 Dec 2025 |
|---|---|---|
Gregory Collier | 9,833,333 | 18,088,594 |
Ross Murdoch | 3,333,333 | 5,669,297 |
Matthew McNamara | 1,666,666 | 5,669,297 |
Paul Gavin | 15,517,507 | 65,885,940 |
Roksan Libinaki | 14,333,332 | 32,235,308 |
Kathy Connell | 0 | 7,162,942 |
Total | 44,684,171 (≈1.2%) | 134,711,378 |
Competitive Landscape
Key Competitors
| # | Competitor | Segment | Positioning versus Avecho | Revenue / scale |
|---|---|---|---|---|
| 1 | Jazz Pharmaceuticals (Epidiolex) | Prescription CBD (epilepsy) | Only major regulator-approved CBD drug; not approved for insomnia; validates pharmaceutical-grade CBD | Very large (multi-billion US$); Epidiolex roughly US$1B a year. |
| 2 | Bod Science Ltd (ASX: BOD) | Australian CBD / medicinal cannabis; Schedule 3 ambitions | Australian peer pursuing CBD medicines; named alongside Avecho as a comparable [3P: GlobalData] | — |
| 3 | Little Green Pharma (ASX: LGP) | Australian medicinal cannabis producer | Prescription-channel cannabis supplier; potential low-dose CBD entrant | — |
| 4 | Botanix Pharmaceuticals (ASX: BOT) | Dermatology (historically topical synthetic CBD) | Former cannabinoid peer, now pivoted; listed as a GlobalData comparable | — |
| 5 | Zelira Therapeutics | Cannabinoid insomnia formulations | Direct cannabinoid-for-insomnia competitor | — |
| 6 | Other Australian Schedule 3 CBD aspirants (various) | OTC CBD | Avecho states that no other Phase III CBD insomnia program is positioned for Schedule 3 registration [ASX 31 Aug 2026]; peers' Phase III sleep studies missed significance [3P: SmallCaps 2023] | — |
| 7 | Merck & Co (Belsomra, suvorexant) | Rx insomnia (orexin antagonist) | Established Rx therapy; Avecho targets an OTC, tolerability-led niche | — |
| 8 | Eisai (Dayvigo, lemborexant) | Rx insomnia | As above | — |
| 9 | Idorsia (Quviviq, daridorexant) | Rx insomnia | As above | — |
| 10 | Neurim / generic melatonin (Circadin) | Rx/OTC sleep aids in Australia | Incumbent pharmacy sleep products in Australia; key OTC substitute | — |
| 11 | Generic hypnotics (zolpidem, temazepam) | Rx insomnia | Low-cost incumbents with dependence and next-day-effect concerns, which supports CBD's tolerability positioning | — |
| 12 | Catalent / Lonza and other solubility-enhancement CDMOs | Drug-delivery platforms | Larger platform providers competing for formulation partnerships | Very large; not relevant at Avecho scale |
Competitor Detail
| Metric | Avecho (FY2025) |
|---|---|
Revenue | A$1.24M |
Revenue growth | +9.3% |
Gross margin | 71.8% |
Net margin | -356.8% |
R&D intensity (R&D / revenue) | 348% |
Late-stage CBD insomnia asset | Yes (Phase III, positive interim) |
Recent Developments
There have been no layoffs, litigation or regulatory actions in the period. The September 2026 quarterly (Appendix 4C) is due by 31 October 2026 and had not been released at the dossier date.



